Prof. Lim Seng Gee
Chairman, Singapore Hepatitis Conference
THE SCIENCE OF
HBV CURE
MEETING 2022
The Science of HBV Cure Meeting Organized by Singapore Hepatology Conference
The Science of
HBV Cure 2022
Hybrid Meeting
The Singapore Hepatology Conference Organizing Committee is delighted to invite you to participate in our sister conference
As in previous live meetings, the Science of HBV Cure 2022 Hybrid Meeting (HBV Cure 2022) will feature an extensive line up of world renowned experts in the field of Science of Hepatitis B Cure. They will share and provide a comprehensive update of their research works.
Thanks to the generous support of our Sponsors, NO registration fee is required.
View the Preliminary Scientific Programme for the HBV Cure 2022 below.
THIS PROGRAM IS BEING SUPPORTED BY MEANS OF AN UNRESTRICTED EDUCATIONAL GRANT BY GILEAD SCIENCES INC.
Welcome Address from Prof. Lim Seng Gee, Chairman
Dear Friends and Colleagues,
I would like to welcome you to the 6th Science of Hepatitis B Cure Symposium to be held each afternoon from 2:00pm to 5:00pm SGT, Monday to Thursday, 30 May to 2 June 2022 (HBV Cure 2022).
This year, HBV Cure 2022 will be held as a Hybrid Meeting with speakers appearing LIVE at our Studio in Singapore or on Zoom, to discuss the latest developments in the Science of HBV Cure. The attendees can attend the meeting from their homes. We hope that the state of the art conferencing technology will enhance the conference experience for both the attendees and speakers and enable even more interactions between them. You will be able to view this exciting program on the website.
As a registrant of HBV Cure 2022, you are also free to join it’s sister conference, SHC 2022 to be held each evening on the same days, ie, from 6.00pm to 10:30pm SGT, Monday to Thursday, 30 May to 2 June 2022.
Prof. Seng Gee Lim
Chairman, Singapore Hepatitis Conference
Meet the Experts
Scientific Programme at a Glance
30 May
The science of functional cure
| Chairs Prof. Seng Gee Lim Prof. Sharon Lewin |
|
| What Can We Learn About HBV Cure From HIV – Prof. Sharon Lewin | 2.00pm – 2.20pm |
| Immunology Of HBV – Prof. Carolina Boni | 2.20pm – 2.40pm |
| DEBATE: cccdna Silencing Or Elimination? FOR Silencing: Prof. Massimo Levrero FOR Elimination: Dr Thomas Tu |
2.40pm – 3.10pm |
| Hepatitis B Virus DNA Integration And Functional Cure – Dr.Thomas Tu | 3.10pm – 3.30pm |
| Transcriptomics Of Functional Cure – Dr. Ram DasGupta | 3.30pm – 3.50pm |
| Q&A | 3.50pm – 4.05pm |
| Free Paper Session | |
| The Application of Long-read Sequencing Technologies to Investigate Structure and Expression of HBV Integrations – Dr. Cameron M. Soulette | 4.05pm – 4.20pm |
| HIV-1 Tat stimulates hepatitis B surface antigen expression in hepatocytes co-infected with HIV and hepatitis B virus – Dr. Wei Zhao | 4.20pm – 4.35pm |
| Codons under positive selection in the S open reading frame of the genotype B2 Hepatitis B Virus – Dr. William Abbott | 4.35pm – 4.50pm |
| Closing remarks | 4.50pm |
31 MAY
New antiviral therapies
| Chairs Prof. Seng Gee Lim Prof. Pietro Lampertico |
|
| Capsid Inhibitor Overview – Prof. Man Fung Yuen | 2.00pm – 2.20pm |
| Progress in the Development in Core Inhibitors for the Treatment of Chronic Hepatitis B Infection – Dr. William Delaney | 2.20pm – 2.40pm |
| Entry Inhibitor For HBV/HDV – Prof. Pietro Lampertico | 2.40pm – 3.00pm |
| Q&A | 3.00pm – 3.20pm |
| Update on AB-729 and AB-836, an siRNA and capsid inhibitor currently in development for the treatment of chronic hepatitis B infection – Dr. Gaston Picchio | 3.20pm – 3.40pm |
| Studying Hepatic distribution of oligonucleotides using Multimodal Imaging Techniques. – Dr. Steve Hood | 3.40pm – 4.00pm |
| Rep Achieving clearance of subviral particles with NAPs: A critical milestone for HBsAg loss and functional cure. – Dr. Andrew Valliant | 4.00pm – 4.20pm |
| Short Interfering RNA JNJ-3989 based combination Therapy in Chronic Hepatitis B – Dr. Oliver Lenz | 4.20pm – 4.40pm |
| Which antiviral strategies for functional cure? An Overview – Prof. Massimo Levrero | 4.40pm – 5.00pm |
| Q&A | 5.00pm |
| Closing remarks | 5.20pm |
1 JUNE
Immune modulation in CHB
| Chairs Prof. Seng Gee Lim Prof. Antonio Bertoletti |
|
| Lessons From HIV-HBV Co-Infection And Functional Cure: Restoration Of Immune Responses – Prof. Sharon Lewin | 2.00pm – 2.20pm |
| Immune Pathways & Mechanisms Leading To Functional Cure – Prof. Carolina Boni | 2.20pm – 2.40pm |
| The Role Of Innate Immunity In Functional Cure – Prof. Fabien Zoulim | 2.40pm – 3.00pm |
| Therapeutic Vaccination And Novel Immunotherapies For Functional Cure – Prof. Antonio Bertoletti | 3.00pm – 3.20pm |
| Gilead: HBV Cure Strategy and Portfolio | 3.20pm – 3.40pm |
| Q&A | 3.40pm – 4.00pm |
| Free Paper Session | |
| Safety, PK, PD and Antiviral Activity of TLR7 Agonist RO7020531 in Patients with Chronic Hepatitis B Not Receiving Antiviral Treatment: a Phase 1 Study (TLR 7 program) – Dr. Filippo Canducci | 4.00pm – 4.15pm |
| Identification and Validation of Hepatitis B Virus Host-Susceptibility Factors – Dr. Collins Oduor Owino | 4.15pm – 4.30pm |
| Comprehensive immune profiling of intrahepatic environment of functionally cured chronic hepatitis B patients revealed altered adaptive immune response and emergence of innate immune responses – Dr. Atefeh Khakpoor | 4.30pm – 4.45pm |
| Closing remarks | 4.45pm – 5.00pm |
2 JUNE
The future of HBV functional cure
| Chairs Prof. Seng Gee Lim Prof. Pei-Jer Chen |
|
| Debate: Immunotherapy Is Not Necessary For Functional Cure For: Prof. Pei-Jer Chen Against: Prof. Antonio Bertoletti |
2.00pm – 2.30pm |
| Promising Preclinical Agents For Functional Cure – Prof. Fabien Zoulim | 2.30pm – 2.50pm |
| Which Combination Therapies For Functional Cure? – Prof. Edward Gane | 2.50pm – 3.10pm |
| Is It Necessary To Achieve Absolute HBV Cure? – Prof. Pei-Jer Chen | 3.10pm – 3.30pm |
| Q&A | 3.30pm |
| Free Paper Session | |
| Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24-week interim data of the Phase 3 MYR301 study – Mr. Jacques YU | 3.50pm – 4.05pm |
| Antiviral effects of oral farnesoid X receptor agonist vonafexor combined with pegylated interferon alpha2a in untreated patients with chronic hepatitis B – Dr. Bettina Hansen | 4.05pm – 4.20pm |
| Closing comments | 4.20pm |
Abstract Submission
The SHC 2022 Organising Committee would like to invite interested parties to present their research papers at the SCIENCE OF HBV CURE MEETING 2022 ONLINE.
Abstracts will be reviewed by the Abstract Selection Committee and accepted submissions will be posted on the Science of HBV Cure Meeting 2022 Online website and the Singapore Hepatology Conference website. Up to 15 Abstracts will be selected by the Abstract Selection Committee for Live Oral presentation during the meeting (ie, approximately (3) presentations each evening). The Presenter of the best oral presentation each evening will be awarded USD 500 while the remaining oral presenters will be awarded USD 200 each (one (1) Presenter per oral presentation per poster).
How to Submit Abstracts
Testimonials
This is my second time attending the Singapore Science of HBV Cure Meeting. The Programme for the Science of HBV Cure meeting has been really fantastic. One of the Highlights today is bringing to the fore the potential of all these new treatments and the discussions on how we are going to combine them. Very good discussions, very good debate. The Science of HBV Cure Meeting really fosters international collaboration. People who should come to this meeting are people across Asia who want to do basic science and clinical research and want to collaborate with people internationally.
Dr. Veronica Miller
Executive Director,
Forum for Collaborative Research, Washington, DC, USA
It’s my 3rd time in the Science of HBV Cure Meeting. I like it because it’s really a very good blend of basic science, translational science, clinicians and people from industry.
The session are very lively, with many communications, there is some flexibility and we end up late but the discussions are never cut and that’s good. There are a lot of new and interesting data and a lot of science being presented as expected because this meeting is called the Science of HBV Cure.
Prof. Massimo Levrero
Professor of Medicine,
Sapienza University, Centre de Recherche en Cancerologie de Lyon (CRCL) Lyon, France
I’m a Scientist based in Singapore and have attended previous Science of HBV Cure Meetings here. The most interesting part of Science of HBV Cure Meeting for me is the immunology part because I work in this field. The meeting is growing every year with more and more international speakers and participants. I think it is a good meeting for young scientists from Asia.
Dr. Nina Le Bert
Senior Research Fellow,
Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore